Take Solutions buys Ecron Acunova to expand into biosimilars space

 
With the coming together of the two organisations, Take will explore new vistas of the dynamic pharmaceutical, biotechnology, and medical device R&D markets including the areas of biosimilars, regenerative medicine and diagnostic imaging agents. Take’s enhanced capabilities will enable it to be an integral part of the fast growing biosimilars space. As an innovation driven organisation, Take Solutions will also now be able to expand its IPs in risk based monitoring and other solutions aimed at bringing safe, effective, and affordable drugs and devices to market.
 
With the acquisition of Ecron Acunova, Take will add audit ready infrastructure in Europe and India, and parts of South Asia to its expanding footprint. The organisation will also augment its pool of subject matter experts by 30 percent and life sciences talent by 50 percent, significantly amplifying its experience, innovation and domain expertise. In addition, the full service capability along with expanded infrastructure will allow Take Solutions to service the mid-market as well.

 
“Take & Ecron Acunova’s combined attributes will strengthen our position as a fully integrated differentiated life sciences services provider to large and small global pharmaceutical companies and thereby broaden the addressable market,” added Srinivasan.
 
Ecron Acunova is a life sciences services company delivering pharmaceutical research services to global clients across South East Asia, Central & Nordic Europe and North America. Along with catering to big pharma clients, EA’s capabilities lay in delivering highly specialised services to small/medium size biotech and pharma companies in the areas of pharmacovigilance, regulatory affairs, strategic consulting, clinical data management and biostatistics, medical writing, clinical trials phases II-IV and bioavailability & bioequivalence (BA/BE).